Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C6H7NO.C4H6O5 |
| Molecular Weight | 243.2133 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | Assumed racemic |
SHOW SMILES / InChI
SMILES
OCC1=CN=CC=C1.OC(CC(O)=O)C(O)=O
InChI
InChIKey=ZTFZMPGWBKSBSL-UHFFFAOYSA-N
InChI=1S/C6H7NO.C4H6O5/c8-5-6-2-1-3-7-4-6;5-2(4(8)9)1-3(6)7/h1-4,8H,5H2;2,5H,1H2,(H,6,7)(H,8,9)
| Molecular Formula | C4H6O5 |
| Molecular Weight | 134.0874 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | C6H7NO |
| Molecular Weight | 109.1259 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Nicotinyl alcohol is a direct-acting vasolidator, that may decrease the blood pressure and it is a cholesterol-lowering agent. Nicotinyl alcohol as a tartrate salt led to the efficiency improvements in patients with intermittent claudication. In addition, nicotinyl alcohol alone or associated with other drugs was studied in the treatment of radicular syndromes; and was shown, that the effect had not been due to mechanical compression.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
Other AEs: Increased appetite, Skin rash... Other AEs: Increased appetite (15%) Sources: Skin rash (36%) Itching (37%) Flushing (68%) Nausea (50%) Abdominal pain (15%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Abdominal pain | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Increased appetite | 15% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Skin rash | 36% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Itching | 37% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Nausea | 50% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
| Flushing | 68% | 600 mg 2 times / day steady, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: steady Dose: 600 mg, 2 times / day Sources: |
unhealthy, 30 - 66 years n = 20 Health Status: unhealthy Condition: hyperlipoproteinemia Age Group: 30 - 66 years Sex: M+F Population Size: 20 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. | 1974 May |
|
| Reaction of the tobacco alkaloid myosmine with hydrogen peroxide. | 2006 Jan |
|
| Picolinyl ester fragmentation mechanism studies with application to the identification of acylcarnitine acyl groups following transesterification. | 2006 Nov |
|
| Enzymatic oxidation of NADP+ to its 4-oxo derivative is a side-reaction displayed only by the adrenodoxin reductase type of ferredoxin-NADP+ reductases. | 2007 Aug |
|
| catena-Poly[[tetrakis(mu-propionato-kappa(2)O:O')dicopper(II)]-mu-3-pyridylmethanol-kappa(2)N:O-[bis(propionato-kappaO)bis(3-pyridylmethanol-kappaN)copper(II)]-mu-3-pyridylmethanol-kappaO:N]. | 2007 Mar |
|
| catena-Poly[[bis-[2-(2,3-dimethyl-anilino)benzoato-κO]cadmium(II)]-di-μ-3-pyridylmethanol-κN:O;κO:N]. | 2008 Feb 6 |
|
| Equilibria of 3-pyridylmethanol with copper(II). A comparative electron spin resonance study by the decomposition of spectra in liquid and frozen solutions. | 2008 Oct 16 |
|
| A rapid and sensitive method for the simultaneous analysis of aliphatic and polar molecules containing free carboxyl groups in plant extracts by LC-MS/MS. | 2009 Nov 25 |
|
| Synthesis and Structural Characterization of a Metal Cluster and a Coordination Polymer Based on the [Mn(6)(mu(4)-O)(2)] Unit. | 2010 |
|
| Noncovalent synthesis of hierarchical zinc phosphates from a single Zn(4)O(12)P(4) double-four-ring building block: dimensionality control through the choice of auxiliary ligands. | 2010 Jan 18 |
|
| Copper (II) complexes of the anti-inflammatory drug naproxen and 3-pyridylmethanol as auxiliary ligand. Characterization, superoxide dismutase and catecholase--mimetic activities. | 2010 Sep |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:58 GMT 2023
by
admin
on
Fri Dec 15 15:35:58 GMT 2023
|
| Record UNII |
W6T0WO5LEJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
137321938
Created by
admin on Fri Dec 15 15:35:59 GMT 2023 , Edited by admin on Fri Dec 15 15:35:59 GMT 2023
|
PRIMARY | |||
|
181074-82-8
Created by
admin on Fri Dec 15 15:35:59 GMT 2023 , Edited by admin on Fri Dec 15 15:35:59 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
W6T0WO5LEJ
Created by
admin on Fri Dec 15 15:35:59 GMT 2023 , Edited by admin on Fri Dec 15 15:35:59 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
